Literature DB >> 19532020

Respiratory syncytial virus and other respiratory viruses in the setting of bone marrow transplantation.

Michael G Ison1.   

Abstract

PURPOSE OF REVIEW: Several epidemiologic studies have enhanced our understanding of the impact of respiratory viruses on bone marrow transplant recipients. RECENT
FINDINGS: Respiratory viral infections occur frequently following stem cell transplantation but present atypically. Many patients have asymptomatic infections. There is a growing armamentarium of antiviral agents currently under development, although prospective studies in transplant patients are needed.
SUMMARY: Respiratory viral infections occur frequently after hematopoietic stem cell transplant. Newer agents may prove useful in the prevention and treatment of respiratory viral infections in this population.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19532020     DOI: 10.1097/CCO.0b013e328324bc1c

Source DB:  PubMed          Journal:  Curr Opin Oncol        ISSN: 1040-8746            Impact factor:   3.645


  8 in total

1.  Prophylactic treatment with a G glycoprotein monoclonal antibody reduces pulmonary inflammation in respiratory syncytial virus (RSV)-challenged naive and formalin-inactivated RSV-immunized BALB/c mice.

Authors:  Gertrud U Radu; Hayat Caidi; Congrong Miao; Ralph A Tripp; Larry J Anderson; Lia M Haynes
Journal:  J Virol       Date:  2010-06-30       Impact factor: 5.103

2.  Effect of Previous Respiratory Syncytial Virus Infection on Murine Immune Responses to F and G Protein-Containing Virus-Like Particles.

Authors:  Lori McGinnes Cullen; Madelyn R Schmidt; Trudy G Morrison
Journal:  J Virol       Date:  2019-04-17       Impact factor: 5.103

3.  Transfer of influenza vaccine-primed costimulated autologous T cells after stem cell transplantation for multiple myeloma leads to reconstitution of influenza immunity: results of a randomized clinical trial.

Authors:  Edward A Stadtmauer; Dan T Vogl; Eline Luning Prak; Jean Boyer; Nicole A Aqui; Aaron P Rapoport; Kenyetta R McDonald; Xiaoling Hou; Heather Murphy; Rita Bhagat; Patricia A Mangan; Anne Chew; Elizabeth A Veloso; Bruce L Levine; Robert H Vonderheide; Abbas F Jawad; Carl H June; Kathleen E Sullivan
Journal:  Blood       Date:  2010-09-23       Impact factor: 22.113

Review 4.  Fourth European Conference on Infections in Leukaemia (ECIL-4): guidelines for diagnosis and treatment of human respiratory syncytial virus, parainfluenza virus, metapneumovirus, rhinovirus, and coronavirus.

Authors:  Hans H Hirsch; Rodrigo Martino; Katherine N Ward; Michael Boeckh; Hermann Einsele; Per Ljungman
Journal:  Clin Infect Dis       Date:  2012-09-28       Impact factor: 9.079

5.  Impact of gut colonization with butyrate-producing microbiota on respiratory viral infection following allo-HCT.

Authors:  Bastiaan W Haak; Eric R Littmann; Jean-Luc Chaubard; Amanda J Pickard; Emily Fontana; Fatima Adhi; Yangtsho Gyaltshen; Lilan Ling; Sejal M Morjaria; Jonathan U Peled; Marcel R van den Brink; Alexander I Geyer; Justin R Cross; Eric G Pamer; Ying Taur
Journal:  Blood       Date:  2018-04-19       Impact factor: 25.476

Review 6.  [Children with cancer and respiratory viral infection: epidemiology, diagnosis and treatment options].

Authors:  Jesús Saavedra-Lozano; Carmen Garrido; Pilar Catalán; Felipe González
Journal:  Enferm Infecc Microbiol Clin       Date:  2010-12-22       Impact factor: 1.731

7.  Prevalence and clinical course of upper airway respiratory virus infection in critically ill patients with hematologic malignancies.

Authors:  Jongmin Lee; Seok Chan Kim; Chin Kook Rhee; Jaewoong Lee; Jong Wook Lee; Dong-Gun Lee
Journal:  PLoS One       Date:  2021-12-14       Impact factor: 3.240

8.  Impact of FilmArray™ Respiratory Panel testing on the clinical management of pediatric bone marrow transplant patients.

Authors:  Mimi R Precit; Kaidi He; Kanokporn Mongkolrattanothai; Babak Moghimi; Marisa Glucoft; Jennifer Dien Bard
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2021-11-24       Impact factor: 5.103

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.